Caribou Biosciences, Inc.
CRBU evidence brief
What we can confirm
- BioSniper Score:
- 6.0 / 10
- Market Cap:
- $136.2M
- Lead Asset:
- CB-010 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for CRBU—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CRBU
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company developing allogeneic CAR-T cell therapies, with its lead candidate vispa-cel (CB-010) in a pivotal phase 3 trial for second-line large B-cell lymphoma.
Key risk: Clinical trial execution risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$136.2M
Cash Runway
—
Lead Asset
CB-010 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for Caribou Biosciences, Inc..
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company developing allogeneic CAR-T cell therapies, with its lead candidate vispa-cel (CB-010) in a pivotal phase 3 trial for second-line large B-cell lymphoma.
- Cash & equivalents of $26.2M as of 2026-06-30 [sec]
- Total revenue of $1.5M and net income of -$24.3M as of 2026-06-30 [sec]
- Lead candidate vispa-cel (CB-010) has RMAT designation for r/r LBCL and Fast Track designation for r/r B-NHL and SLE [pipeline]
- Phase 1 data for vispa-cel presented at EHA 2026 showed safety, efficacy, and durability on par with approved autologous CAR-T therapies [news · published 2026-08-13]
- CB-011 (allogeneic anti-BCMA CAR-T) is in phase 1 CaMMouflage trial for r/r multiple myeloma, with dose expansion initiated in late 2025 [sec_mda · as of 2026-08-13]
What works
- Vispa-cel has achieved FDA alignment on a pivotal phase 3 trial design (ANTLER-3) for second-line LBCL, indicating regulatory progress [news · published 2026-05-07]
- Phase 1 data for vispa-cel presented at EHA 2026 demonstrated safety and efficacy comparable to approved autologous CAR-T therapies [news · published 2026-08-13]
- CB-011 showed deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients in dose escalation data presented at EHA 2026 [news · published 2026-08-13]
What to weigh
- The company has not yet generated revenue from product sales and may never achieve regulatory approval for any candidate [sec_mda · as of 2026-08-13]
- Net losses were $24.3M for the quarter ended June 30, 2026, and expenses are expected to increase substantially as clinical trials advance [sec_mda · as of 2026-08-13]
- Cash & equivalents of $26.2M as of June 30, 2026 may be limited relative to the anticipated increase in clinical trial costs [sec]
From the filings
Quoted directly from source documents.
Vispa-cel has FDA alignment on pivotal phase 3 trial design
“Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL”
News · May 7, 2026
Phase 1 data for vispa-cel presented at EHA 2026
“ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies”
News · August 13, 2026
CB-011 dose escalation data presented at EHA 2026
“CaMMouflage dose escalation phase 1 data presented at EHA 2026 demonstrate single dose of CB-011 produced deep, durable responses in high-risk, late-line BCMA-naïve r/r MM patients”
News · August 13, 2026
Cash position as of June 30, 2026
“.9 million as of June 30, 2026”
SEC MD&A · August 13, 2026
Risks & what to watch (4)›
Key risks
- Clinical trial execution risk — Uncertainties in cost, timing, and outcomes of clinical trials, especially the pivotal phase 3 ANTLER-3 trial [sec · filed 2026-06-11]
- Regulatory approval uncertainty — The company may never achieve regulatory approval for any product candidate [sec_mda · as of 2026-08-13]
- Cash runway constraints — Cash & equivalents of $26.2M as of June 30, 2026 may be insufficient to fund increasing clinical trial expenses [sec]
- Competitive landscape — CB-012 faces at least 8 competitors in the r/r AML space, including other phase 2 trials [pipeline]
What to watch
- Initiation and progress of the pivotal phase 3 ANTLER-3 trial for vispa-cel [news · published 2026-05-07]
- Longer follow-up data from vispa-cel phase 1 expected at a medical conference in 2026 [news · published 2026-05-07]
- Dose expansion data for CB-011 from the CaMMouflage phase 1 trial expected in 2026 [news · published 2026-05-07]
- Cash burn rate and any new financing or partnership announcements given $26.2M cash as of June 30, 2026 [sec]
Sources: News · Pipeline · SEC filings · SEC MD&A · Generated October 10, 2026 · How we verify sources →
Run Caribou Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Caribou Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.46 · 0% dilution
Lead: Phase 1
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 7.5%
- Days to cover
- 4.9
- Shares short
- 7,123,813
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CRBU short interestGovernance
Frequently asked questions
What is the AI investment thesis for Caribou Biosciences, Inc.?
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company developing allogeneic CAR-T cell therapies, with its lead candidate vispa-cel (CB-010) in a pivotal phase 3 trial for second-line large B-cell lymphoma.
What is Caribou Biosciences, Inc.'s lead drug candidate?
Caribou Biosciences, Inc.'s most advanced tracked candidate is CB-010 (Phase 1) for second-line relapsed or refractory large B cell lymphoma (r/r LBCL).
Who is the CEO of Caribou Biosciences, Inc.?
Dr. Rachel E. Haurwitz Ph.D. is the chief executive officer of Caribou Biosciences, Inc. (CRBU).
Where is Caribou Biosciences, Inc. headquartered?
Caribou Biosciences, Inc. (CRBU) is headquartered in Berkeley, CA, United States.
What therapeutic areas does Caribou Biosciences, Inc. focus on?
Caribou Biosciences, Inc. develops therapies across Oncology, Gene Therapy.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.